Interested in sponsorship and exhibition opportunities at the 4th Clinical Trials Phase I & Phase IIA Summit? Reach out to David Finkel, Business Development Director, at firstname.lastname@example.org or 917-242-3898 to learn more.
ARENSIA EXPLORATORY MEDICINE is a German company entirely specialized to address a strategic market niche, namely the high need for FAST PATIENT RECRUITMENT in Phase I / II / PROOF OF CONCEPT clinical trials.
ARENSIA runs its own network of seven modern Phase I units located in large Eastern European University Hospitals (Romania, Moldova and Georgia) focused on the performance of complex protocols First-in-Patient SAD/MAD across numerous therapeutic areas: e.g. ONCOLOGY, IMMUNOLOGY, NEUROSCIENCES, RESPIRATORY, INFECTIOUS DISEASES, CARDIOVASCULAR/METABOLIC, GI, etc.
ARENSIA has a strong reputation for providing reliable, extraordinary fast patient recruitment (incl. biological/treatment naïve patients) and high quality data.
This allows our Sponsors to minimize the number of involved sites, which results in major time and budget savings.
Clinical Trials of Texas, Inc. (CTT) is a San Antonio-based multitherapeutic research site, founded in 2001 by President/CEO Kay Scroggins, RN, CCRC. CTT conducts approximately 120 trials a year in phases I-IV, working with more than 15 doctors in metabolic disorders, mental health, women’s health, dermatology and Alzheimer’s disease. CTT also features an inclusive 6,000 foot, 20+ bed facility for early phase services.
Covance Inc., the drug development business of Laboratory Corporation of America Holdings (LabCorp) headquartered in Princeton, New Jersey, USA, is the world’s most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®. Information on Covance’s solutions can be obtained through its website at www.covance.com.
High Point Clinical Trials Center has provided comprehensive (Phase I-III) clinical site services since 2008. Our 42,000ft 2 facility consists of three unique units for the execution of outpatient and inpatient clinical studies. In addition to healthy normal Phase I studies, we focus on specialty populations such as Metabolic Diseases, Respiratory, CNS, Cardiovascular and Nicotine-related.
inSeption’s insistence upon securing the “right” people to integrate into a true partnership alliance with its clients eliminates the vulnerability so often felt by operational leaders faced with evaluating traditional outsourcing options. inSeption’s core competency of identifying and securing the most experienced and proficient professionals builds the crucial foundation of a successful drug development program. Actively collaborating with its clients to custom design, hand select and assemble high-performing project teams empowers inSeption to tailor its services specifically to meet the needs of their programs. The inSeption model provides increased control, full transparency of project deliverables and timelines, and significant operational and cost efficiencies.